Rachel Lutz writes in MD Magazine that researchers from the Ichan School of Medicine at Mount Sinai in New York have concluded that the anti-seizure drug ezogabine can reduce symptoms associated with major depressive disorder (MDD). The investigators studied 18 adult patients with MDD to determine how ezogabine would impact their symptoms. Read Ms. Lutz’ article for the full story. Ezogabine was developed by GSK and Valeant Pharmaceuticals.
Lead Research/InvestigatorSource: MD Mag